Core Viewpoint - Myopia among adolescents has become a global public health issue, with over 50% prevalence in China, necessitating new intervention methods beyond existing treatments like low-concentration atropine eye drops [1][2]. Group 1: Current Challenges in Myopia Prevention - Low-concentration atropine effectively delays myopia progression by approximately 60% but only controls axial length growth by about 30%, indicating a significant limitation [2]. - The dual effects of atropine include measurement bias due to its dilation effect and a compensatory response that may lead to pathological elongation of the eyeball [2]. Group 2: Discovery of Crocetin - A groundbreaking study from Japan identified Crocetin as a potent activator of EGR-1, a key transcription factor in regulating cell proliferation and differentiation, which may intervene in myopia progression [3]. - In a mouse model, Crocetin significantly reduced axial length growth compared to the control group [5]. Group 3: Clinical Trials and Efficacy - A clinical study involving 67 children aged 6-12 showed that daily oral administration of 7.5mg Crocetin for six months resulted in a significant increase in choroidal thickness compared to the control group [8][10]. - The increase in choroidal thickness is crucial as it improves retinal metabolic conditions and inhibits scleral hypoxic expansion [10]. Group 4: Mechanisms of Action - Crocetin's effects may be attributed to multiple pathways, including EGR-1 activation, antioxidant stress response, and improved choroidal blood flow [11][13]. - Both spherical equivalent refraction and axial length measurements showed significant improvement in the Crocetin group compared to controls [12]. Group 5: Advantages and Future Prospects - Crocetin offers several advantages over traditional drugs, including its natural origin, safety for long-term use, and multi-target action addressing both axial length and refractive error [14]. - Ongoing multi-center clinical trials in China aim to validate the efficacy of different doses of Crocetin for children, with potential complementary use alongside low-concentration atropine [14]. - The development of precise drug delivery systems, such as nano-sustained release eye drops, may position Crocetin as a key player in altering the course of myopia [15].

Core Viewpoint - The leading ophthalmic drug company, Xingqi Eye Medicine, reported significant growth in its 2024 financial results, driven primarily by the successful launch of its myopia treatment, atropine sulfate eye drops, which has become a key growth engine for the company [1][4]. Financial Performance - In 2024, the company achieved a total revenue of 1.943 billion yuan, marking a year-on-year increase of 32.42% [2]. - The net profit attributable to shareholders reached 338 million yuan, reflecting a growth of 40.84% [2]. - The net profit after deducting non-recurring gains and losses was 347 million yuan, with a growth rate of 44.54% [2]. - The gross profit margin improved to 78.33%, an increase of 0.96 percentage points compared to the previous year [6]. Product Performance - The "myopia miracle drug," atropine sulfate eye drops (marketed as "Mei Ou Pin"), saw its revenue in the eye drop segment surge by 106.08% year-on-year following its approval for use in children aged 6-12 [4][6]. - The company has a diverse product line with 60 approved ophthalmic drug products, of which 38 are included in the medical insurance directory [6]. Market Competition - The market is becoming increasingly competitive, with rivals such as Hengrui Medicine and Zhaoke Ophthalmology nearing the launch of similar products, which could impact Xingqi's market share [3][8]. - Alternative solutions like orthokeratology lenses are also diverting patients, creating a dual challenge for the company [9]. - The company is responding to competition by enhancing its R&D and channel strategies, including advancing clinical trials for different concentrations of atropine eye drops [9]. Strategic Initiatives - The company plans to build a comprehensive service ecosystem to address the competitive landscape in the 300 billion yuan youth myopia prevention market, moving from a single product focus to a platform-based development approach [9].